STOCK TITAN
  1. Home
  2. Sec-filings
  3. PRAX
  4. [8-K] Praxis Precision Medicines, Inc. Reports Material Event

Praxis (PRAX) teams with Remagine Labs on transdermal ulixacaltamide for essential tremor

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Praxis Precision Medicines entered a research collaboration and license agreement with Remagine Labs to develop an iontophoretic transdermal patch to deliver ulixacaltamide for essential tremor. The patch will use Remagine’s electronically controlled, multi-day dosing platform to complement Praxis’s lead oral ulixacaltamide program.

The goal of adding a transdermal option is to broaden the patient population ulixacaltamide can reach and support its competitive positioning and long-term franchise value. Praxis also made an equity investment in Remagine, reinforcing their commitment to advance this delivery approach alongside ongoing clinical development.

Positive

  • None.

Negative

  • None.

Insights

Praxis deepens ulixacaltamide franchise with Remagine delivery pact.

Praxis is expanding its ulixacaltamide strategy beyond oral dosing by partnering with Remagine Labs on an iontophoretic transdermal patch for essential tremor. This leverages Remagine’s electronically controlled, multi-day dosing platform to create an alternative, device-based route of administration.

A transdermal format can be important in movement disorders, where swallowing or adherence challenges limit oral therapies. The filing also notes an equity investment in Remagine, aligning incentives and signaling commitment to this approach, although no financial terms or timelines are disclosed in the excerpt.

The collaboration’s relevance ultimately depends on clinical performance of both oral and patch formulations and on regulatory outcomes. Future company filings describing trial design, early data, or device development milestones will clarify how central this patch becomes to the overall ulixacaltamide franchise.

Item 8.01 Other Events Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
research collaboration and license agreement financial
"announced that the Company entered into a research collaboration and license agreement"
iontophoretic transdermal patch technical
"to develop an iontophoretic transdermal patch for the delivery of ulixacaltamide"
electronically controlled transdermal drug delivery systems technical
"Remagine Labs, Inc., a developer of electronically controlled transdermal drug delivery systems"
ulixacaltamide medical
"to develop an iontophoretic transdermal patch for the delivery of ulixacaltamide for essential tremor"
essential tremor medical
"for the delivery of ulixacaltamide for essential tremor"
Essential tremor is a neurological condition that causes involuntary shaking, usually in the hands or arms, which can make everyday tasks difficult. While it is not life-threatening, it can impact a person's ability to perform precise movements. For investors, understanding such health conditions is important because they can influence a person's productivity, decision-making, and overall financial stability.
forward-looking statements regulatory
"contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995"
Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.

FAQ

What new collaboration did Praxis Precision Medicines (PRAX) announce?
Praxis announced a research collaboration and license agreement with Remagine Labs. The partnership focuses on developing an iontophoretic transdermal patch using Remagine’s electronically controlled platform to deliver ulixacaltamide for essential tremor, complementing Praxis’s existing lead oral ulixacaltamide program.

What is the goal of the Praxis and Remagine iontophoretic transdermal patch?
The goal is to create a transdermal option for delivering ulixacaltamide to patients with essential tremor. Using Remagine’s multi-day active dosing platform, the patch is intended to broaden the patient population reached and support ulixacaltamide’s competitive positioning and long-term franchise value.

How does this collaboration affect Praxis Precision Medicines’ ulixacaltamide program?
The collaboration adds a new delivery route to Praxis’s lead oral ulixacaltamide program. By pairing the drug with an iontophoretic transdermal patch, Praxis aims to offer more flexible dosing options, potentially improving access for patients who may struggle with or prefer alternatives to oral medication.

Did Praxis Precision Medicines invest in Remagine Labs as part of this agreement?
Yes, Praxis made an equity investment in Remagine Labs alongside the collaboration. This investment is described as underscoring both companies’ shared commitment to quickly advance the transdermal ulixacaltamide program, more closely aligning their interests around successful development and potential commercialization.

What risks does Praxis highlight regarding this ulixacaltamide collaboration?
Praxis notes that statements about the collaboration and ulixacaltamide’s potential market opportunity are forward-looking. It highlights uncertainties inherent in clinical trials and refers investors to risk factors in its Form 10-K for the year ended December 31, 2025 and other SEC filings for additional details.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Understanding 8-K Material Events →
FALSE000168954800016895482026-07-072026-07-07

 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): July 7, 2026
PRAXIS PRECISION MEDICINES, INC.
(Exact name of registrant as specified in its charter)
 
Delaware
001-39620
47-5195942
(State or other jurisdiction
of incorporation)
(Commission
File Number)
(I.R.S. Employer
Identification No.)

Praxis Precision Medicines, Inc.
99 High Street, 30th Floor
Boston, Massachusetts 02110
(Address of principal executive offices, including zip code)
(617) 300-8460
(Registrant’s telephone number, including area code)
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
 
Title of each class 
Trade
Symbol(s)
 
Name of each exchange
on which registered
Common Stock, $0.0001 par value per share PRAX The Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company  ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐
 
 


Item 8.01. Other Events.
On July 7, 2026, Praxis Precision Medicines, Inc. (the “Company”) announced that the Company entered into a research collaboration and license agreement (the “Agreement”) with Remagine Labs, Inc., a developer of electronically controlled transdermal drug delivery systems (“Remagine”), to develop an iontophoretic transdermal patch for the delivery of ulixacaltamide for essential tremor. Under the Agreement, the Company and Remagine will collaborate to apply Remagine’s proprietary platform, designed for precise, multi-day active transdermal dosing, to ulixacaltamide, complementing the Company’s lead oral program. A transdermal option is intended to broaden the population ulixacaltamide can reach, while strengthening ulixacaltamide’s competitive positioning and extending the long-term value of the franchise. The Company has also made an equity investment in Remagine, underscoring the companies’ shared commitment to quickly advancing the program.
Forward-Looking Statements
This Current Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding the Company’s strategic collaboration with Remagine and the development and potential market opportunity of ulixacaltamide. The forward-looking statements included in this Current Report on Form 8-K are subject to a number of risks, including, without limitation, uncertainties inherent in clinical trials and other risks as described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025 and other filings with the Securities and Exchange Commission. These statements are based only on facts currently known by the Company and speak only as of the date of this Current Report on Form 8-K. As a result, you are cautioned not to rely on these forward-looking statements and the Company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments or otherwise.




SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
PRAXIS PRECISION MEDICINES, INC.
Date: July 7, 2026By: /s/ Marcio Souza
 Marcio Souza
 Chief Executive Officer

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

3 documents

Other Documents